- Report
- December 2024
- 150 Pages
Global
From €5324EUR$5,950USD£4,608GBP
- Report
- July 2025
- 281 Pages
Global
From €5234EUR$5,850USD£4,531GBP
- Report
- July 2025
- 364 Pages
Global
From €5234EUR$5,850USD£4,531GBP
- Report
- April 2025
- 183 Pages
Global
From €3422EUR$3,825USD£2,962GBP
€4026EUR$4,500USD£3,485GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1790EUR$2,000USD£1,549GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €2237EUR$2,500USD£1,936GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1118EUR$1,250USD£968GBP
- Report
- December 2024
- 84 Pages
Global
From €3534EUR$3,950USD£3,059GBP
- Report
- January 2025
- 200 Pages
Global
From €4469EUR$4,995USD£3,869GBP
- Report
- November 2018
- 147 Pages
Global
From €2461EUR$2,750USD£2,130GBP
- Report
- July 2024
- 202 Pages
Global
From €5324EUR$5,950USD£4,608GBP
- Report
- May 2024
- 139 Pages
Global
From €5815EUR$6,499USD£5,033GBP
- Report
- October 2023
- 145 Pages
Global
From €2818EUR$3,150USD£2,440GBP
- Report
- October 2023
- 145 Pages
Global
From €2818EUR$3,150USD£2,440GBP
- Report
- November 2023
- 189 Pages
Global
From €3422EUR$3,825USD£2,962GBP
€4026EUR$4,500USD£3,485GBP
- Report
- July 2023
- 135 Pages
Global
From €6711EUR$7,500USD£5,809GBP
- Report
- February 2024
- 168 Pages
Global
From €7113EUR$7,950USD£6,157GBP
- Report
- July 2023
- 67 Pages
Global
From €3534EUR$3,950USD£3,059GBP
- Report
- February 2024
- 112 Pages
Global
From €4250EUR$4,750USD£3,679GBP
- Report
- November 2023
- 140 Pages
Global
From €3185EUR$3,560USD£2,757GBP
€3982EUR$4,450USD£3,447GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more